Ipamorelin vs Tirzepatide: Growth Hormone vs Metabolic Peptide

Ipamorelin is a pentapeptide that selectively stimulates growth hormone release from the pituitary gland:

Selective GHS Action: Ipamorelin binds to ghrelin receptors (GHSR) on pituitary somatotroph cells, triggering GH release in clean, physiological pulses. Crucially, it does this without significantly raising cortisol, prolactin, or ACTH — making it the most selective GH secretagogue available.

Pulsatile GH Release: Unlike exogenous GH injection, Ipamorelin triggers the body's own GH production in a pulsatile pattern that mimics natural physiology.

Research Applications: Body composition optimisation, sleep quality improvement, recovery support, bone density research, and anti-ageing studies.

ORYN Format: €109 for a 30-day pen containing 6mg of pharmaceutical-grade Ipamorelin with >99% purity.

Tirzepatide is a dual GIP/GLP-1 receptor agonist representing the cutting edge of metabolic peptide science:

Dual Receptor Action: Unlike semaglutide (GLP-1 only), Tirzepatide activates both GIP and GLP-1 receptors. GIP enhances fat metabolism and lipid handling in adipose tissue. GLP-1 controls appetite, insulin release, and gastric emptying.

Clinical Evidence: SURPASS and SURMOUNT trials demonstrate weight reductions of 15-21% — the most effective pharmacological weight loss data ever published.

ORYN Format: €169 for a 30-day pen containing 10mg of pharmaceutical-grade Tirzepatide. Also available as a MediT Pen (40mg, €249) for weekly dosing.

Choose Ipamorelin if: - Your research focuses on growth hormone biology - Body composition via GH/IGF-1 pathways is the endpoint - Sleep quality and recovery are key research variables - Budget is a consideration (€109 vs €169)

Choose Tirzepatide if: - Metabolic research is your primary focus - Weight management and appetite regulation are key endpoints - Blood sugar regulation and insulin sensitivity are relevant - You want the most clinically validated weight loss compound available